We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Simulations Plus Wins Phase II Small Business Innovation Research Grant

Simulations Plus Wins Phase II Small Business Innovation Research Grant

Simulations Plus Wins Phase II Small Business Innovation Research Grant

Simulations Plus Wins Phase II Small Business Innovation Research Grant

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Simulations Plus Wins Phase II Small Business Innovation Research Grant"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Simulations Plus, Inc. has announced that it was notified by the National Cancer Institute (NCI) that the company has been awarded a $525,000 Phase II Small Business Innovation Research (SBIR) grant.

The grant, which is disbursed over two years, is for Simulations Plus to further enrich the predictive capabilities of its best-in-class ADMET Predictor™ software product. ADMET Predictor is a software research tool used worldwide by pharmaceutical scientists to estimate absorption, distribution, metabolism, excretion, and toxicity properties of pharmaceutical compounds and to build advanced mathematical models.

Dr. Robert Fraczkiewicz, team leader for ADMET Cheminformatics for Simulations Plus and principal investigator for the grant, said: “This Phase II grant extends the development and validation of our novel very fast method of calculating quantum atomic and molecular descriptors – important properties of new drug molecules that govern how they interact with each other and their environment.”

He continued, “The importance of the method we are developing cannot be overstated since these parameters are essential for accurate predictive modeling of molecular properties, especially in the areas of metabolism and toxicity. Independent comparison studies have shown ADMET Predictor models to be the most accurate in the world and we have now developed a novel method to further improve on them. Prior to our Phase I effort, calculating quantum descriptors of sufficient quality required enormous amounts of computer time.”

“In our Phase I effort we developed commercially valuable calculation methods that are orders of magnitude faster and yet accurate enough to provide improved prediction of a number of properties for new drug-like molecules. These calculations have already been commercially deployed in our latest release of ADMET Predictor and are in use by customers world-wide,” said Fraczkiewicz.

The primary objectives of the government’s SBIR program are to stimulate technological innovations in the private sector and to strengthen the role of small businesses in meeting federal research and development needs.